Jim Simons Regeneron Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

$62.3 Billion
Q1 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 78,901 shares of REGN stock, worth $43.8 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

78,901

Previous 247,743 68.15%

Holding current value

$43.8 Million

Previous $176 Million 71.64%

% of portfolio

0.08%

Previous 0.28%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$634.14 - $744.83 $107 Million - $126 Million	-168,842 Reduced 68.15%	78,901 $50 Million
Q4 2024 Feb 13, 2025	BUY	$701.85 - $1046.91 $25.5 Million - $38 Million	36,320 Added 17.18%	247,743 $176 Million
Q3 2024 Nov 13, 2024	BUY	$1024.09 - $1201.76 $26.9 Million - $31.6 Million	26,261 Added 14.18%	211,423 $222 Million
Q2 2024 Aug 09, 2024	BUY	$883.2 - $1071.19 $17.5 Million - $21.2 Million	19,800 Added 11.97%	185,162 $195 Million
Q1 2024 May 13, 2024	SELL	$902.69 - $993.35 $70.1 Million - $77.2 Million	-77,700 Reduced 31.97%	165,362 $159 Million
Q4 2023 Feb 13, 2024	BUY	$775.18 - $881.7 $62.8 Million - $71.4 Million	81,000 Added 49.98%	243,062 $213 Million
Q3 2023 Nov 14, 2023	BUY	$692.45 - $844.37 $51.1 Million - $62.4 Million	73,862 Added 83.74%	162,062 $133 Million
Q2 2023 Aug 11, 2023	SELL	$700.03 - $830.35 $18.7 Million - $22.2 Million	-26,700 Reduced 23.24%	88,200 $63.4 Million
Q1 2023 May 12, 2023	SELL	$680.49 - $826.97 $52.1 Million - $63.3 Million	-76,541 Reduced 39.98%	114,900 $94.4 Million
Q4 2022 Feb 13, 2023	SELL	$705.89 - $766.39 $12 Million - $13 Million	-16,959 Reduced 8.14%	191,441 $138 Million
Q3 2022 Nov 14, 2022	SELL	$573.97 - $724.32 $215 Million - $271 Million	-374,662 Reduced 64.26%	208,400 $144 Million
Q2 2022 Aug 12, 2022	BUY	$548.35 - $738.84 $166 Million - $224 Million	303,200 Added 108.34%	583,062 $345 Million
Q1 2022 May 13, 2022	SELL	$595.12 - $698.43 $1.84 Million - $2.17 Million	-3,100 Reduced 1.1%	279,862 $195 Million
Q4 2021 Feb 11, 2022	BUY	$543.48 - $670.97 $98.8 Million - $122 Million	181,700 Added 179.44%	282,962 $179 Million
Q3 2021 Nov 12, 2021	BUY	$574.03 - $680.96 $58.1 Million - $69 Million	101,262 New	101,262 $61.3 Million
Q2 2021 Aug 13, 2021	SELL	$472.8 - $558.54 $30.8 Million - $36.4 Million	-65,152 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$446.73 - $548.2 $375 Million - $460 Million	-839,800 Reduced 92.8%	65,152 $30.8 Million
Q4 2020 Feb 10, 2021	SELL	$478.3 - $607.98 $80.1 Million - $102 Million	-167,410 Reduced 15.61%	904,952 $437 Million
Q3 2020 Nov 13, 2020	BUY	$544.75 - $658.21 $99.3 Million - $120 Million	182,262 Added 20.48%	1,072,362 $600 Million
Q2 2020 Aug 13, 2020	BUY	$493.32 - $643.92 $199 Million - $259 Million	402,738 Added 82.64%	890,100 $555 Million
Q1 2020 May 14, 2020	BUY	$336.18 - $494.43 $66.9 Million - $98.4 Million	198,962 Added 68.99%	487,362 $238 Million
Q4 2019 Feb 13, 2020	SELL	$274.13 - $376.51 $30.3 Million - $41.6 Million	-110,418 Reduced 27.69%	288,400 $108 Million
Q3 2019 Nov 13, 2019	BUY	$273.46 - $318.39 $16.6 Million - $19.4 Million	60,856 Added 18.01%	398,818 $111 Million
Q2 2019 Aug 12, 2019	BUY	$299.6 - $414.82 $38.9 Million - $53.8 Million	129,700 Added 62.28%	337,962 $106 Million
Q1 2019 May 14, 2019	SELL	$372.08 - $439.57 $52.7 Million - $62.2 Million	-141,600 Reduced 40.47%	208,262 $85.5 Million
Q4 2018 Feb 13, 2019	BUY	$335.82 - $403.04 $117 Million - $141 Million	349,862 New	349,862 $131 Million

Others Institutions Holding REGN

# of Institutions

1,445

Shares Held

84.8M

Call Options Held

1.4M

Put Options Held

1.42M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $59.4B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account